Over half of trial patients in EU marketing submissions are from third countries
This article was originally published in SRA
Executive Summary
Some 61% of the patients who took part in the pivotal clinical trials used to support marketing authorisation applications submitted to the European Medicines Agency between 2005 and 2009 came from third countries, a report by the agency has revealed1. In addition, since 1997, good clinical practice inspections have been requested for only 228 of the 44,034 investigator sites counted as part of the pivotal trials in these MAAs, illustrating the very small sample of sites that are, or can be, inspected.
You may also be interested in...
New Evidence For Kisqali Secures Funding In England For Second-Line Use
The decision by health technology assessment body NICE on Novartis’s advanced breast cancer drug, Kisqali, contrasts sharply with its recommendation for another CDK4/6 inhibitor – Lilly’s Verzenios.
Dostarlimab, Zynteglo & COVID-19 Combo Drugs In The Spotlight At EMA
The sponsors of seven new drugs are set to find out this week whether the European Medicines Agency’s human medicines committee, the CHMP, will recommend pan-EU approval for their products. CHMP action is also expected regarding two potential combination therapies for COVID-19.
Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: